A comparison of daily average consumption of oxycodone controlled release (OxyContin CR) and oxymorphone extended release (opana ER) in patients with low back pain

P and T

Volumn 36, Issue 3, 2011, Pages 139-144

  Berner, Todd ^a   Thomson, Heather ^a   Hartry, Ann ^a   Puenpatom, R Amy ^a   Ben Joseph, Rami ^a   Szeinbach, Sheryl L ^b  

^a Health Outcomes and PharmacoEconomics   (United States)

^b OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

OXYCODONE; OXYMORPHONE;

ADULT; ARTICLE; CONTROLLED DRUG RELEASE; DISEASE CLASSIFICATION; DRUG USE; FEMALE; GEOGRAPHIC DISTRIBUTION; HUMAN; LOW BACK PAIN; MAJOR CLINICAL STUDY; MALE; PRESCRIPTION;

EID: 79953006960     PISSN: 10521372     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. World Health Organization. WHO Treatment Guidelines on Nonmalignant Pain in Adults, 2008. Available at: www.who.int/ medicines/areas/quality-safety/ Scoping-WHOGuide-non-malignant-pain-adults.pdf. Accessed August 25, 2010.
2. Kalso E, Laurie A, Dellemijn PLI, et al. Recommendations for using opioids in chronic non-cancer pain. Eur J Pain 2003;7:381-386. (Pubitemid 37101777)
3. Paulose-Ram R, Hirsh R, Dillon C, et al. Prescription and nonprescription analgesic use among the U.S. adult population: Results from the Third National Health and Nutrition Examination Survey (NHANES III). Pharmacoepidemiol Drug Saf 2003;12:315-326. (Pubitemid 36700608)
4. Portenoy RK, Farrar JT, Backonja M, et al. Long-term use of controlled-release oxycodone for noncancer pain: Results of a 3-year registry study. Clin J Pain 2007;23(4):287-299. (Pubitemid 46650020)
5. Federation of State Medical Boards: Model policy for the use of controlled substances for the treatment of pain, 2004. Available at: www.fsmb.org/pdf/2004-grpol-Controlled-Substances.pdf. Accessed August 25, 2010.
6. Guidelines for Chronic Pain Management. An Updated Report by the American Society of Anesthesiologists Task Force on Chronic Pain Management and the American Society of Regional Anesthesia and Pain Medicine. Anesthesiology 2010;112(4):810-833.
7. Sullivan MD, Edlund MJ, Fan Ming-Yu, et al. Trends in use of opioids for non-cancer pain conditions 2000-2005 in commercial and Medicaid insurance plans: The TROUP study. Pain 2008;138:440-449.
8. National Center for Health Statistics. Health, United States, 2007 with Chartbook on Trends in the Health of Americans. Hyattsville, Md.: U.S. Dept of Health and Human Services, Centers for Disease Control and Prevention; 2007.
9. Hart LG, Deyo RA, Cherkin DC. Physician office visits for low back pain: Frequency, clinical evaluation, and treatment patterns from a U.S. national survey. Spine 1995;20:11-19.
10. Vogt MT, Kwoh K, Cope DK, et al. Analgesic usage for low back pain: Impact on health care costs and service use. Spine 2005; 30(9):1075-1081. (Pubitemid 40663916)
11. Jamison R, Raymond S, Slawsby E, et al. Opioid therapy for chronic non-cancer back pain: A randomized prospective study. Spine 1998;23:2591-2600. (Pubitemid 29003533)
12. Hale ME, Dvergsten C, Gimbel J. Efficacy and safety of oxymorphone extended-release in chronic low back pain: Results of a randomized, double blind, placebo- and active-controlled study. J Pain 2005;6(1):21-28. (Pubitemid 40051998)
13. Martell B, O'Connor P, Kerns R, et al. Systematic review: Opioid treatment for chronic back pain. Prevalence, efficacy, and association with addiction. Ann Intern Med 2007;146:116-127.
14. Olsen Y, Baumit GL, Ford DE. Opioid prescriptions by U.S. primary care physicians from 1992 to 2001. J Pain 2006;7(4):225-235.
15. Katz N, Adams E, Chilcoat H, et al. Challenges in the development of prescription opioid abuse-deterrent formulations. Clin J Pain 2007;238:648-660. (Pubitemid 47462170)
16. Morden NE, Zerzan JT, Rue TC, et al. Medicaid prior authorization and controlled-release oxycodone. Med Care 2008;46(9):573-580.
17. Katz MH, Kotabe S. Decreasing use of controlled-release oxycodone: Response to Morden, et al. Med Care 2008;46(9):1002.
18. Holzworth A. Impact of an OxyContin formulary change on member opioid utilization and prescriber practices. Poster presented at the Academy of Managed Care Pharmacy, 22nd Annual Meeting & Showcase, San Diego, April 7-10, 2010.
19. McAdam-Marx C, Bouchard J, Brixner DI. Comparison of daily insulin dose and other anti-diabetic medications usage for type 2 diabetes patients treated with an analog basal insulin. Curr Med Res Opin 2010;26(1):191-201.
20. Borah BJ, Darkow T, Bouchard J, et al. A comparison of insulin use, glycemic control, and health care costs with insulin detemir and insulin glargine in insulin-naïve patients with type 2 diabetes. Clin Ther 2009;31(3):623-631.
21. Jan SA, Patel JV, Welz J, Ishak P. A retrospective database analysis of prescribing patterns for specific angiotensin receptor blockers. Drug Benefit Trends 2005;17:23-29. (Pubitemid 40394599)
22. Schnitzer TJ, Kong SX, Mitchell JH, et al. An observational, retrospective, cohort study of dosing patterns for rofecoxib and celecoxib in the treatment of arthritis. Clin Ther 2003;25(12):3162-3172. (Pubitemid 38096153)
23. Turk D, Okifuji A. Pain terms and taxonomies of pain. In: Fishman S, Ballantyne J, Rathmell J (eds). Bonica's Management of Pain, 4th ed. Philadelphia: Lippincott Williams & Wilkins; 2010.
24. Thielke S, Simoni-Wastila L, Edlund M, et al. Age and sex trends in long-term opioid use in two large American health systems between 2000 and 2005. Pain Med 2010;11:248-256.
25. OxyContin (oxycodone HCl controlled-release tablets), prescribing information. Stamford, Conn.: Purdue Pharma; 2010. Available at: www.purduepharma.com/pi/prescription/oxycontin. pdf. Accessed August 25, 2010.
26. Opana ER (oxymorphone HCl extended-release tablets), prescribing information. Chadds Ford, Pa.: Endo Pharmaceuticals; 2008. Available at: www.endo.com/pdf/Opana-ER-PI.pdf. Accessed August 25, 2010.
27. Hall WH, Ramachandran R, Narayan S, et al. An electronic application for rapidly calculating Charlson co-morbidity score. BMC Cancer 2004;4:94.
28. Charlson ME, Pompei P, Ales K, MacKenzie CR. A new method of classifying prognostic co-morbidity in longitudinal studies: Development and validation. J Chron Dis 1987;40:373-383. (Pubitemid 17055592)
29. Hale M, Fleischman R, Salzman R, et al. Efficacy and safety of controlled- release versus immediate-release oxycodone: Randomized, double-blinded evaluation in patients with chronic back pain. Clin J Pain 1999;15(3):179-183. (Pubitemid 29467548)
30. Watson C, Moulin D, Watt-Watson J, et al. Controlled-release oxycodone relieves neuropathic pain: A randomized controlled trial in painful diabetic neuropathy. Pain 2003;105:71-78. (Pubitemid 37162475)
31. Mandema JW, Kaiko RF, Oshlack B, et al. Characterization and validation of a pharmacokinetic model for controlled-release oxycodone. Br J Clin Pharmacol 1996;42:747-756. (Pubitemid 26417617)
32. Adams M, Adhieh H. Pharmacokinetics and dose-proportionality of oxymorphone extended-release and its metabolites: Results of a randomized cross-over study. Pharmacotherapy 2004;24(4):468-476. (Pubitemid 38420533)
33. Sellers E, Schoedel KA, McMorn S, et al. Oral intact extended-release oxymorphone is associated with less liking and lower positive subjective effects than equianalgesic doses of oral intact controlled-release oxycodone in healthy nondependent recreational opioid users. J Pain 2010;11(4):S21.
34. Katz N, Panas L, Kim ML, et al. Usefulness of prescription monitoring programs for surveillance analysis of schedule II opioid prescription data in Massachusetts, 1996-2006. Pharmaco - epidemiol Drug Saf 2010;19:115-123.
35. Pergolizzi JV Jr, Labhsetwar SA, Puenpatom RA, et al. Prevalence of exposure to potential CYP450 pharmacokinetic drug-drug interactions among patients with chronic low back pain taking opioids. Pain Practice, August 26, 2010 (online).
36. White A, Birnbaum H, Mareva M, et al. Direct costs of opioid abuse in an insured population in the United States. J Manag Care Pharm 2005;11(6):469-479.
37. Saunders K, Dunn K, Merrill J, et al. Relationship of opioid use and dosage levels to fractures in older chronic pain patients. J Gen Intern Med 2010;25(4):310-315.
38. Dunn K, Saunders K, Rutter C, et al. Opioid prescriptions for chronic pain and overdose. Ann Intern Med 2010;152(2):85-92.